Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 7, 2016, Pages 926-934

  Ratzer, Rikke ^a   Iversen, Pernille ^a   Börnsen, Lars ^a   Dyrby, Tim B ^a   Romme Christensen, Jeppe ^a   Ammitzbøll, Cecilie ^a   Madsen, Camilla Gøbel ^a   Garde, Ellen ^a   Lyksborg, Mark ^a   Andersen, Birgit ^a   Hyldstrup, Lars ^a   Sørensen, Per Soelberg ^a   Siebner, Hartwig R ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cerebrospinal fluid; clinical trial; magnetization transfer ratio; methylprednisolone; osteopontin; Progressive multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE; OSTEOPONTIN; ALENDRONIC ACID; CALCIUM; VITAMIN D; AUTACOID; BIOLOGICAL MARKER; GLUCOCORTICOID; SPP1 PROTEIN, HUMAN;

ACNE; ADULT; ARTICLE; BONE DENSITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG EFFECT; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; EDEMA; FEMALE; HEART PALPITATION; HOT FLUSH; HUMAN; INSOMNIA; MALE; METALLIC TASTE; MOTOR EVOKED POTENTIAL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; AGED; CELL COUNT; CEREBROSPINAL FLUID; CLINICAL OUTCOME; COLORIMETRY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMYELINATION; DIFFUSION TENSOR IMAGING; DISEASE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUSHING; HYPERTRANSAMINASEMIA; INFLAMMATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ADOLESCENT; CLINICAL TRIAL; CONVALESCENCE; DENMARK; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; NEUROLOGIC EXAMINATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RECURRENT DISEASE; TIME FACTOR; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BIOMARKERS; BONE DENSITY; DENMARK; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; EVOKED POTENTIALS, MOTOR; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROLOGIC EXAMINATION; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PULSE THERAPY, DRUG; RECOVERY OF FUNCTION; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973494486     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515605908     Document Type: Article

References (19)

1. Mahad DH, Trapp BD, Lassmann H,. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14: 183-193.
2. Romme Christensen J, Bornsen L, Ratzer R, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression. PLoS One 2013; 8: e57820.
3. Szalardy L, Zadori D, Simu M, et al. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J Neurol Sci 2013; 331: 38-42.
4. Romme Christensen J, Bornsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2012; 19: 877-884.
5. Bornsen L, Khademi M, Olsson T, et al. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011; 17: 32-42.
6. Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82: 1499-1507.
7. Cazzato G, Mesiano T, Antonello R, et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 1995; 35: 193-98.
8. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51: 239-245.
9. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-250.
10. Ravnborg M, Gronbech-Jensen M, Jonsson A,. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis. Mult Scler 1997; 3: 31-42.
11. Bjorner JB, Damsgaard MT, Watt T, et al. Tests of data quality, scaling assumptions, and reliability of the Danish SF-36. J Clin Epidemiol 1998; 51: 1001-1011.
12. De SN, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015; 22. pii: jnnp-2014-309903. [Epub ahead of print]
13. De SN, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868-1876.
14. Sellebjerg F, Sorensen TL,. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003; 61: 347-355.
15. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001; 124: 2540-2549.
16. Rocca MA, Mastronardo G, Rodegher M, et al. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 1999; 20: 821-827.
17. Filippi M, Rocca MA,. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics 2007; 4: 401-413.
18. Ratzer R, Romme CJ, Romme NB, et al. Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. J Neuroimmunol 2014; 276: 195-201.
19. Comi G,. Disease-modifying treatments for progressive multiple sclerosis. Mult Scler 2013; 19: 1428-1436.